Expression of FOXP1 and cyclinE in primary central nervous system lymphoma and its significance.
- Author:
Lin SHEN
1
;
Bo-bin CHEN
;
Zi CHEN
;
Xiao-ping XU
;
Guo-wei LIN
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Central Nervous System Neoplasms; genetics; metabolism; Cyclin E; genetics; metabolism; Female; Forkhead Transcription Factors; genetics; metabolism; Humans; Lymphoma, Non-Hodgkin; genetics; metabolism; Male; Middle Aged; Prognosis; Repressor Proteins; genetics; metabolism; Retrospective Studies; Survival Rate
- From: Chinese Journal of Hematology 2012;33(8):648-652
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the value of FOXP1 and Cyclin E gene in primary central nervous system lymphoma(PCNSL) of immunocompetent patients on prognostic significance.
METHODSClinical data of 71 patients with newly diagnosed PCNSL from 2002 to 2007 was analyzed retrospectively. Immunohistochemistry method (HRP-EnVision(TM)) was performed to observe the expression of FOXP1 and Cyclin E gene in tumor tissue samples. The survival was analyzed by Kaplan-Meier survival curve, survival factors analysis by the Log-rank test and COX proportional hazards regression model.
RESULTSFOXP1 positive was observed in 35 of 51 patients (68.63%) and Cyclin E staining was present in 29 of 50 cases (58.00%). FOXP1(+) patients had a shorter overall survival (OS) than FOXP1(-) ones. 2-year OS rate in FOXP1(+) and FOXP1(-) patients were 23.33% and 73.56%, respectively(P = 0.0015). Cyclin E(+) patients had a shorter overall survival(OS) than cyclinE(-) ones. 2-year OS rate in Cyclin E(+) and Cyclin E(-) patients were 17.56% and 69.76%, respectively (P = 0.0017). Multivariate analysis showed that Cyclin E expression was an independent prognostic factor for shorter OS (P = 0.048). FOXP1 expression might be an important prognostic factor for shorter OS (P = 0.065).
CONCLUSIONCyclin E expression is an independent prognostic factor and FOXP1 expression is a possible prognostic factor for poor clinical outcome in patients with PCNSL.
